Results
1 -
10 of
26Xu Tianfeng, Peng Ting, Ren Xiaomei, Zhang Lianwen, Yu Lei, Luo Jinfeng, Zhang Zhang, Tu Zhengchao, Tong Linjiang, Huang Zhaoru, Lu Xiaoyun, Geng Meiyu, Xie Hua, Ding Jian, Ding Ke.
C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant, Med. Chem. Commun., 2015 Overcoming EGFR-TKI Resistance, Guide to Targeted Therapies: Treatment Resistance in Lung Cancer Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK, Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways EGFR Mutant, Molecular Targeted Therapy of Lung Cancer Liquid biopsy: unlocking the potentials of cell-free DNA, Virchows Archiv Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer, Targeted Oncology Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer, Targeted Oncology Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer, Targeted Oncology New strategies to develop new medications for lung cancer and metastasis, Cancer and Metastasis Reviews